S&P 500   3,391.85 (+0.64%)
DOW   29,392.79 (+0.55%)
QQQ   237.33 (+1.11%)
AAPL   324.38 (+1.69%)
FB   217.78 (+-0.01%)
MSFT   187.31 (+0.04%)
GOOGL   1,528.88 (+0.62%)
AMZN   2,184.19 (+1.32%)
CGC   21.63 (-1.41%)
NVDA   312.51 (+5.37%)
BABA   223.25 (+1.24%)
MU   59.73 (+3.43%)
GE   12.85 (+0.78%)
TSLA   918.04 (+6.95%)
AMD   59.01 (+3.73%)
T   38.64 (+0.99%)
F   8.02 (-0.50%)
NFLX   387.75 (+-0.01%)
PRI   136.24 (+0.46%)
BAC   34.79 (+1.52%)
DIS   141.19 (+1.47%)
GILD   67.02 (+0.01%)
S&P 500   3,391.85 (+0.64%)
DOW   29,392.79 (+0.55%)
QQQ   237.33 (+1.11%)
AAPL   324.38 (+1.69%)
FB   217.78 (+-0.01%)
MSFT   187.31 (+0.04%)
GOOGL   1,528.88 (+0.62%)
AMZN   2,184.19 (+1.32%)
CGC   21.63 (-1.41%)
NVDA   312.51 (+5.37%)
BABA   223.25 (+1.24%)
MU   59.73 (+3.43%)
GE   12.85 (+0.78%)
TSLA   918.04 (+6.95%)
AMD   59.01 (+3.73%)
T   38.64 (+0.99%)
F   8.02 (-0.50%)
NFLX   387.75 (+-0.01%)
PRI   136.24 (+0.46%)
BAC   34.79 (+1.52%)
DIS   141.19 (+1.47%)
GILD   67.02 (+0.01%)
S&P 500   3,391.85 (+0.64%)
DOW   29,392.79 (+0.55%)
QQQ   237.33 (+1.11%)
AAPL   324.38 (+1.69%)
FB   217.78 (+-0.01%)
MSFT   187.31 (+0.04%)
GOOGL   1,528.88 (+0.62%)
AMZN   2,184.19 (+1.32%)
CGC   21.63 (-1.41%)
NVDA   312.51 (+5.37%)
BABA   223.25 (+1.24%)
MU   59.73 (+3.43%)
GE   12.85 (+0.78%)
TSLA   918.04 (+6.95%)
AMD   59.01 (+3.73%)
T   38.64 (+0.99%)
F   8.02 (-0.50%)
NFLX   387.75 (+-0.01%)
PRI   136.24 (+0.46%)
BAC   34.79 (+1.52%)
DIS   141.19 (+1.47%)
GILD   67.02 (+0.01%)
S&P 500   3,391.85 (+0.64%)
DOW   29,392.79 (+0.55%)
QQQ   237.33 (+1.11%)
AAPL   324.38 (+1.69%)
FB   217.78 (+-0.01%)
MSFT   187.31 (+0.04%)
GOOGL   1,528.88 (+0.62%)
AMZN   2,184.19 (+1.32%)
CGC   21.63 (-1.41%)
NVDA   312.51 (+5.37%)
BABA   223.25 (+1.24%)
MU   59.73 (+3.43%)
GE   12.85 (+0.78%)
TSLA   918.04 (+6.95%)
AMD   59.01 (+3.73%)
T   38.64 (+0.99%)
F   8.02 (-0.50%)
NFLX   387.75 (+-0.01%)
PRI   136.24 (+0.46%)
BAC   34.79 (+1.52%)
DIS   141.19 (+1.47%)
GILD   67.02 (+0.01%)
Log in

NASDAQ:ADVM - Adverum Biotechnologies Stock Price, Forecast & News

$16.28
-0.04 (-0.25 %)
(As of 02/19/2020 12:49 PM ET)
Today's Range
$16.07
Now: $16.28
$16.70
50-Day Range
$9.87
MA: $11.71
$15.79
52-Week Range
$3.52
Now: $16.28
$16.79
Volume41,939 shs
Average Volume1.70 million shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.68
Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADVM
CUSIPN/A
Phone650-656-9323

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.61 million
Book Value$3.20 per share

Profitability

Net Income$-72,630,000.00

Miscellaneous

Employees82
Market Cap$1.05 billion
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.


Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies Inc (NASDAQ:ADVM) issued its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.25) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.02. The biotechnology company earned $0.25 million during the quarter, compared to the consensus estimate of $0.48 million. View Adverum Biotechnologies' Earnings History.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Adverum Biotechnologies.

What price target have analysts set for ADVM?

7 Wall Street analysts have issued 12 month price objectives for Adverum Biotechnologies' shares. Their forecasts range from $13.00 to $21.00. On average, they anticipate Adverum Biotechnologies' share price to reach $18.80 in the next year. This suggests a possible upside of 15.1% from the stock's current price. View Analyst Price Targets for Adverum Biotechnologies.

What is the consensus analysts' recommendation for Adverum Biotechnologies?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adverum Biotechnologies.

Has Adverum Biotechnologies been receiving favorable news coverage?

News headlines about ADVM stock have been trending somewhat negative this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Adverum Biotechnologies earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Adverum Biotechnologies.

Are investors shorting Adverum Biotechnologies?

Adverum Biotechnologies saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 7,710,000 shares, an increase of 6.2% from the January 15th total of 7,260,000 shares. Based on an average daily volume of 1,080,000 shares, the days-to-cover ratio is currently 7.1 days. Approximately 14.8% of the shares of the company are sold short. View Adverum Biotechnologies' Current Options Chain.

Who are some of Adverum Biotechnologies' key competitors?

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Endologix (ELGX), Immunomedics (IMMU), Amarin (AMRN), Nextera Energy Partners (NEP), Aegean Marine Petroleum Network (ANW) and Chipotle Mexican Grill (CMG).

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the folowing people:
  • Dr. Mehdi Gasmi, Pres & Chief Scientific Officer (Age 52)
  • Dr. Mitchell H. Finer, Co-Founder & Director (Age 60)
  • Dr. Amber Salzman, Consultant (Age 57)
  • Ms. Leone D. Patterson, CEO & Director (Age 56)
  • Mr. Thomas Leung, Chief Financial Officer

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by many different of institutional and retail investors. Top institutional investors include Kam Lawrence (6.26%), State Street Corp (4.83%), UBS Group AG (4.36%), Renaissance Technologies LLC (2.25%), Goldman Sachs Group Inc. (1.77%) and Victory Capital Management Inc. (1.27%). Company insiders that own Adverum Biotechnologies stock include James Paul Scopa and Mehdi Gasmi. View Institutional Ownership Trends for Adverum Biotechnologies.

Which institutional investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Rafferty Asset Management LLC, Citigroup Inc., Jane Street Group LLC, Tower Research Capital LLC TRC and New York State Common Retirement Fund. View Insider Buying and Selling for Adverum Biotechnologies.

Which institutional investors are buying Adverum Biotechnologies stock?

ADVM stock was purchased by a variety of institutional investors in the last quarter, including Kam Lawrence, Goldman Sachs Group Inc., UBS Group AG, Rhenman & Partners Asset Management AB, Barclays PLC, Frazier Management LLC, UBS Asset Management Americas Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for Adverum Biotechnologies.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $16.34.

How big of a company is Adverum Biotechnologies?

Adverum Biotechnologies has a market capitalization of $1.06 billion and generates $1.61 million in revenue each year. The biotechnology company earns $-72,630,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Adverum Biotechnologies employs 82 workers across the globe.View Additional Information About Adverum Biotechnologies.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is http://www.adverum.com/.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company can be reached via phone at 650-656-9323 or via email at [email protected]


MarketBeat Community Rating for Adverum Biotechnologies (NASDAQ ADVM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  333 (Vote Underperform)
Total Votes:  637
MarketBeat's community ratings are surveys of what our community members think about Adverum Biotechnologies and other stocks. Vote "Outperform" if you believe ADVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel